Dr. Rafael Fonseca of the Mayo Clinic Scottsdale discusses today's and tomorrow's myeloma genetic approaches image

Dr. Rafael Fonseca of the Mayo Clinic Scottsdale discusses today's and tomorrow's myeloma genetic approaches

Posted on: Oct 14, 2013
Play Episode
Also available on
Description

Radio Dr. Rafael Fonseca, MD, Mayo Clinic Scottsdale Interview date: October 11, 2013

Dr. Rafael Fonseca describes his research focus on genetic markers for myeloma and how they can become predictors for disease type and progression. He shares his belief that MGUS starts quite early, possibly even as early as childhood and that other genetic triggers cause it to become myeloma. He explains myeloma tests and how he and the Mayo Clinic focus more heavily on the FISH test and the gene expression profile test to determine risk and prognosis over cytogenetics. He notes that half of MGUS patients have translocations (or places where chromosomes have swapped places) and describes how that translocation will never change, even if secondary genetic markets change after treatment. He predicts that gene sequencing will be the up-and-coming approach to help find what "triggers" inactive MGUS to turn into myeloma. He also describes how a gene-specific approach is still early in its use but cites a study example of where this has already been done (the Cereblon gene's effect when using IMID drugs like lenalidomide).  He describes the patients' need to educate themselves and specific questions they can ask to make sure their FISH test and gene expression profile are done correctly.  He shares the wide range of active clinical trials at the Mayo Clinic - from MGUS to smoldering and then to advanced disease stage using a variety of approaches including combination therapies, a monoclonal anti-CD38 study as well as an early gene-targeted study called CDK5. He also explains a study using NAB-Paclitaxel (an iteration of Taxol, a drug used for other cancers) that is used for advanced myeloma resistant to other therapies.    The live mPatient Radio podcast with Dr. Rafael Fonseca

Overview

Radio Dr. Rafael Fonseca, MD, Mayo Clinic Scottsdale Interview date: October 11, 2013 

Dr. Rafael Fonseca describes his research focus on genetic markers for myeloma and how they can become predictors for disease type and progression. He shares his belief that MGUS starts quite early, possibly even as early as childhood and that other genetic triggers cause it to become myeloma. He explains myeloma tests and how he and the Mayo Clinic focus more heavily on the FISH test and the gene expression profile test to determine risk and prognosis over cytogenetics. He notes that half of MGUS patients have translocations (or places where chromosomes have swapped places) and describes how that translocation will never change, even if secondary genetic markets change after treatment. He predicts that gene sequencing will be the up-and-coming approach to help find what "triggers" inactive MGUS to turn into myeloma. He also describes how a gene-specific approach is still early in its use but cites a study example of where this has already been done (the Cereblon gene's effect when using IMID drugs like lenalidomide).  He describes the patients' need to educate themselves and specific questions they can ask to make sure their FISH test and gene expression profile are done correctly.  He shares the wide range of active clinical trials at the Mayo Clinic - from MGUS to smoldering and then to advanced disease stage using a variety of approaches including combination therapies, a monoclonal anti-CD38 study as well as an early gene-targeted study called CDK5. He also explains a study using NAB-Paclitaxel (an iteration of Taxol, a drug used for other cancers) that is used for advanced myeloma resistant to other therapies.    The live mPatient Radio podcast with Dr. Rafael Fonseca

On this episode
Healthtree contact Rafael Fonseca, MD

Rafael Fonseca, MD

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center…

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in Internal Medicine at the University of Miami, FL, and a fellowship in Hematology and Medical Oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a Clinical Investigator for the Damon Runyon Cancer Research Fund. Dr Fonseca’s practice and research have focused on the diagnosis and treatment of plasma cell disorders. He leads the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr Fonseca has led his team of researchers to better understand the genetic nature of malignant plasma cells, real world evidence analysis, myeloma bone disease, prognostic markers, pharmacoeconomics and development of new therapies for the disease. He is an active participant and leader of myeloma clinical trials. He also has served as consultant to multiple companies including AbbVie, Adaptive Biotechnologies, Amgen, Apple, BMS, GSK, Janssen, Karyopharm, Pfizer, Regeneron, and Sanofi. He is a member of the Scientific Advisory Board of Caris Life Sciences, Ryght, Fortvita and Xenagos. He is a member of the Board of Directors for Antengene. He holds the patent for FISH prognostication in myeloma. He has over 400 peer reviewed publications with an associated H index of 135 with 73,278 citations (Google Scholar October 2026). Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. He is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. He was awarded in 2023 the Cyril-Rozman prize by the Spanish Society of Hematology and Hematotherapy. He was awarded a Doctor honoris causa by the Universidad de San Pablo, Argentina in February 2023. He was inducted into the Giants of Cancer Care in 2024. Dr Fonseca holds memberships and has served in positions for organizations such as the ASCO, ASH and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE, CPTAC U01), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, and the Damon Runyon Cancer Research Fund, Paula and Rodger Riney Foundation and others. Dr Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor.
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Transcript

Related Content